Eventide logo

Eventide

North America, Massachusetts, United States, Boston

Description

Eventide is an asset management company that provides investment services for individuals, financial advisors, and institutions.

Investor Profile

Eventide has made 48 investments, with 5 in the past 12 months and 25% as lead.

Stage Focus

  • Series B (35%)
  • Series C (25%)
  • Post Ipo Equity (13%)
  • Private Equity (6%)
  • Series D (6%)
  • Series Unknown (6%)
  • Series E (4%)
  • Series A (4%)

Country Focus

  • United States (92%)
  • Switzerland (4%)
  • United Kingdom (2%)
  • France (2%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Life Science
  • Medical Device
  • Biopharma
  • Pharmaceutical
  • Health Diagnostics
  • Diabetes
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Eventide frequently co-invest with?

Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 16
Farallon Capital Management
North America, California, United States, San Francisco
Co-Investments: 7
CA
North America, Massachusetts, United States, Boston
Co-Investments: 6
RTW Investments
North America, New York, United States, New York
Co-Investments: 7
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 9
CH
North America, New York, United States, New York
Co-Investments: 8
Novo Holdings
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 7
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 10
Soleus Capital
North America, Connecticut, United States, Greenwich
Co-Investments: 8
Sands Capital Ventures
North America, Virginia, United States, Arlington
Co-Investments: 8

Which angels does Eventide often collaborate with?

JT
North America, California, United States, San Francisco
Shared Deals: 1

What are some of recent deals done by Eventide?

Beta Bionics

Irvine, California, United States

Beta Bionics is a biotechnology company that provides software to reduce the burden of diabetes care.

BiotechnologyDiabetesMedical Device
Series ENov 13, 2024
Amount Raised: $60,000,000
Inventiva Pharma

Daix, Bourgogne, France

Inventiva is a biopharmaceutical company with several drug candidates at clinical and preclinical stage.

BiopharmaBiotechnologyClinical TrialsMedicalMedical Device
Post Ipo EquityOct 14, 2024
Amount Raised: $126,004,765
PreciseDx

New York, New York, United States

PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology.

Health Care
Series BAug 21, 2024
Amount Raised: $20,700,000
Kestra Medical Technologies, Inc.

Kirkland, Washington, United States

Kestra Medical Technologies offers wearable medical devices which collects, store, and communicate patients vital performance data.

Health CareHealth DiagnosticsMedical Device
Private EquityJul 24, 2024
Amount Raised: $196,000,000
Celcuity

Hamel, Minnesota, United States

Celcuity is a biotechnology company translating discoveries of new cancer sub-types into expanded therapeutic options for cancer patients.

BiotechnologyHealth CareHealth DiagnosticsTherapeutics
Post Ipo EquityMay 30, 2024
Amount Raised: $60,000,000
LEXEO Therapeutics

New York, New York, United States

LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.

BiotechnologyLife ScienceTherapeutics
Post Ipo EquityMar 11, 2024
Amount Raised: $95,000,000
Freenome

South San Francisco, California, United States

Freenome is a biotechnology company with a comprehensive multiomics platform for cancer detection using a routine blood draw.

BiotechnologyHealth CareHealth DiagnosticsPersonal Health
Series UnknownFeb 15, 2024
Amount Raised: $254,000,000
Sudo Biosciences

Carmel, Indiana, United States

Sudo Biosciences is a biopharma company that designs and develops medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain.

BiopharmaBiotechnologyHealth CareLife ScienceMedical
Series BFeb 13, 2024
Amount Raised: $30,000,000
Sudo Biosciences

Carmel, Indiana, United States

Sudo Biosciences is a biopharma company that designs and develops medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain.

BiopharmaBiotechnologyHealth CareLife ScienceMedical
Series BDec 20, 2023
Amount Raised: $116,000,000
VYNE Therapeutics

Menlo Park, California, United States

VYNE Therapeutics is a clinical late-stage biopharmaceutical company developing treatments associated with dermatologic conditions.

Health CarePharmaceuticalTherapeutics
Post Ipo EquityOct 30, 2023
Amount Raised: $88,000,000